Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections.
The impact of bacterial genetic characteristics on the outcome of patients with Staphylococcus aureus infections is uncertain. This investigation evaluated potential associations between bacterial genotype and clinical outcome using isolates collected as part of an international phase 2 clinical trial (FAST II) evaluating telavancin for the treatment of complicated skin and skin structure infections (cSSSI). Ninety S. aureus isolates from microbiologically evaluable patients with cSSSI enrolled in the FAST II trial from 11 sites in the United States (56 isolates, or 62%) and 7 sites in South Africa (34 isolates, or 38%) were examined for staphylococcal cassette chromosome mec, agr, and the presence of 31 virulence genes and subjected to pulsed-field gel electrophoresis (PFGE). South African methicillin-susceptible S. aureus (MSSA) isolates were more likely to carry certain virulence genes, including sdrD (P = 0.01), sea (P < 0.01), and pvl (P = 0.01). All 44 (49%) methicillin-resistant S. aureus (MRSA) isolates were from the United States; 37 (84%) were strain USA 300 by PFGE. In the United States, MRSA isolates were more likely than MSSA isolates to carry genes for sdrC (P = 0.03), map/eap (P = 0.05), fnbB (P = 0.11), tst (P = 0.02), sea (P = 0.04), sed (P = 0.04), seg (P = 0.11), sej (P = 0.11), agr (P = 0.09), V8 (P = 0.06), sdrD, sdrE, eta, etb, and see (P < 0.01 for all). MRSA isolates were more often clonal than MSSA isolates by PFGE. Isolates from patients who were cured were significantly more likely to contain the pvl gene than isolates from patients that failed or had indeterminate outcomes (79/84 [94%] versus 3/6 [50%]; P = 0.01). S. aureus strains from different geographic regions have different distributions of virulence genes.
Campbell
Steven J
SJ
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Deshmukh
Hitesh S
HS
Nelson
Charlotte L
CL
Bae
In-Gyu
IG
Stryjewski
Martin E
ME
Federspiel
Jerome J
JJ
Tonthat
Giang T
GT
Rude
Thomas H
TH
Barriere
Steven L
SL
Corey
Ralph
R
Fowler
Vance G
VG
D000328:Adult; D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000235:genetics; D016172:DNA Fingerprinting; D004269:DNA, Bacterial / Q000235:genetics; D016521:Electrophoresis, Gel, Pulsed-Field; D005260:Female; D005838:Genotype; D006801:Humans; D000077427:Lipoglycopeptides; D008297:Male; D016106:Methicillin Resistance / Q000235:genetics; D008875:Middle Aged; D017720:Molecular Epidemiology; D046915:Penicillin-Binding Proteins; D013019:South Africa; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000145:classification / Q000235:genetics* / Q000302:isolation & purification; D015534:Trans-Activators / Q000235:genetics; D016896:Treatment Outcome; D014481:United States; D037521:Virulence Factors / Q000235:genetics*
C095698:Agr protein, Staphylococcus aureus; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D000077427:Lipoglycopeptides; D046915:Penicillin-Binding Proteins; D015534:Trans-Activators; D037521:Virulence Factors; C487789:mecA protein, Staphylococcus aureus; C487637:telavancin